TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28438182

Group type: EXPERIMENTAL
Intervention: Forced fluid removal with a therapeutic target of negative net fluid balance ≥1 mL/kg/h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forced fluid removal
Number of subjects: 0
Study: 25346373

Group type: EXPERIMENTAL
Intervention: T-GLY
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CHX-GLY
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: NT-GLY
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: T-PC
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PW-GLY
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PW-PC
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CHX-PC
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: NT-PC
Number of subjects: 6
Study: 22560371

Group type: EXPERIMENTAL
Intervention: D-cycloserine (50mg once weekly)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: D-cycloserine (0mg, placebo)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 29
Study: 20664274

Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 19
Study: 17701037

Group type: EXPERIMENTAL
Intervention: Gemcitabine 400 mg/m2 (dose level 0)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gemcitabine 200 mg/m2 (dose level -1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Non-hematologic toxicity
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hematologic toxicity at dose level 0
Number of subjects: 12
Study: 16089221

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (H2O2) mouth rinse
Number of subjects: 37

Group type: COMPARATOR
Intervention: Water rinse (control)
Number of subjects: 37
Study: 12613268

Group type: EXPERIMENTAL
Intervention: Esberitox N (herbal immunomodulator), dosage: 3 x 2 tablets daily, duration: from 3 days prior to injection to 2 weeks after injection
Number of subjects: 346

Group type: COMPARATOR
Intervention: Placebo, dosage: 3 x 2 tablets daily, duration: from 3 days prior to injection to 2 weeks after injection
Number of subjects: 346
Study: 11910665

Group type: EXPERIMENTAL
Intervention: CEE therapy (0.625 mg/day of conjugated equine estrogen)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: CEE/MPA therapy (0.625 mg/day of CEE and 2.5 mg/day of medroxyprogesterone acetate)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 8730943

Group type: EXPERIMENTAL
Intervention: Antidepressants and behavioural counselling
Number of subjects: 68
Study: 1924235

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 10% isoniazid solution
Number of subjects: 126

Group type: COMPARATOR
Intervention: Oral isoniazid
Number of subjects: 126
Study: 7110846

Group type: EXPERIMENTAL
Intervention: Footrest vibration
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Backrest vibration
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Footrest-backrest vibration combined
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study: 30421573

Group type: EXPERIMENTAL
Intervention: HPV-based screening with Abbot RealTime hrHPV test and cytology triage
Number of subjects: 46708

Group type: COMPARATOR
Intervention: Conventional Pap cytology screening
Number of subjects: 46708
Study: 30550174

Group type: EXPERIMENTAL
Intervention: MoCA (Montreal Cognitive Assessment)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Serum NPY levels
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group re-testing of MoCA
Number of subjects: 72
Study: 27021451

Group type: EXPERIMENTAL
Intervention: Corticotomy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Piezocision
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (contralateral sides)
Number of subjects: 20
Study: 24933729

Group type: EXPERIMENTAL
Intervention: Seven types of orthotic materials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Material brand, density, cell volume, and thickness of orthotic materials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed performance index for insole materials
Number of subjects: 0
Study: 22294737

Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA supplementation (fish oil capsules providing 900 mg of n-3 LCPUFA daily)
Number of subjects: 706

Group type: COMPARATOR
Intervention: Control (matched vegetable oil capsules without n-3 LCPUFA)
Number of subjects: 706
Study: 18802718

Group type: EXPERIMENTAL
Intervention: 2.3% buffered hypertonic seawater
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Buffered isotonic saline solution
Number of subjects: 45

Group type: COMPARATOR
Intervention: Non-buffered isotonic saline
Number of subjects: 45
Study: 16551896

Group type: EXPERIMENTAL
Intervention: 5-day opioid weaning using oral methadone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10-day opioid weaning using oral methadone
Number of subjects: 0
Study: 12923131

Group type: EXPERIMENTAL
Intervention: Methotrexate and Mifepristone (600 mg given orally)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Methotrexate and Placebo
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Methotrexate and Mifepristone (600 mg given orally) with progesterone level >/=10 ng/l
Number of subjects: 212

Group type: COMPARATOR
Intervention: Methotrexate and Placebo with progesterone level >/=10 ng/l
Number of subjects: 212
Study: 10942740

Group type: EXPERIMENTAL
Intervention: DDDR pacing
Number of subjects: 67

Group type: COMPARATOR
Intervention: VDD pacing
Number of subjects: 67
Study: 8775573

Group type: EXPERIMENTAL
Intervention: Pre-exercise glycerol hydration (1.2 gm/kg glycerol in 26 ml/kg solution)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Pre-exercise placebo hydration (26 ml/kg of aspartame flavored water)
Number of subjects: 18
Study: 1428611

Group type: EXPERIMENTAL
Intervention: Modified ultrasonic inserts
Number of subjects: 10

Group type: COMPARATOR
Intervention: Unmodified ultrasonic inserts
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hand instruments
Number of subjects: 10
Study: 3972529

Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 105

Group type: COMPARATOR
Intervention: metrizoate
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: both
Number of subjects: 105
Study: 30716446

Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg every 12 hours (q12h)
Number of subjects: 1199

Group type: COMPARATOR
Intervention: Ceftaroline fosamil 600 mg every 8 hours (q8h)
Number of subjects: 1199
Study: 30390706

Group type: EXPERIMENTAL
Intervention: Restrictive standardized strategy (interval evaluation and stepwise selection for laparoscopic cholecystectomy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (standard practice according to physician's knowledge and experience)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Restrictive standardized strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 27178144

Group type: EXPERIMENTAL
Intervention: Automatic segmentation of breast target
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25005331

Group type: EXPERIMENTAL
Intervention: Whey protein pre-load (50 g whey in 250 ml water)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (250 ml water)
Number of subjects: 15
Study: 22887019

Group type: EXPERIMENTAL
Intervention: HQK-1001 at 10 or 20 mg/kg doses
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HQK-1001 at 30 mg/kg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 20103538

Group type: EXPERIMENTAL
Intervention: Parental presence in the PACU
Number of subjects: 300

Group type: COMPARATOR
Intervention: Parent absent in the PACU
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Parental presence or absence in the PACU
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Age <5 years
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Higher Children's Hospital of Eastern Ontario Pain Scale score at 15 minutes after arrival
Number of subjects: 300

Group type: COMPARATOR
Intervention: Parent absent group
Number of subjects: 300
Study: 18631246

Group type: EXPERIMENTAL
Intervention: Enamel matrix protein derivative (EMD) applied during access flap surgery
Number of subjects: 39

Group type: COMPARATOR
Intervention: Access flap surgery without EMD
Number of subjects: 39
Study: 16133954

Group type: EXPERIMENTAL
Intervention: Loperamide 2 mg/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Loperamide 4 mg/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Loperamide 6 mg/day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11896377

Group type: EXPERIMENTAL
Intervention: Bone-setting
Number of subjects: 114

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 114

Group type: COMPARATOR
Intervention: Light exercise therapy
Number of subjects: 114
Study: 10396858

Group type: COMPARATOR
Intervention: I-131 therapy
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: I-131 therapy + external beam radiotherapy (RT)
Number of subjects: 408
Study: 7554308

Group type: EXPERIMENTAL
Intervention: GH replacement (0.125 IU/kg/week for the first month and 0.25 IU/kg/week thereafter)
Number of subjects: 63
Study: 1974505

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg once daily for 4 weeks
Number of subjects: 118

Group type: COMPARATOR
Intervention: Atenolol 50 mg once daily for 4 weeks
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg once daily + HCTZ 25 mg once daily for 10 weeks
Number of subjects: 118

Group type: COMPARATOR
Intervention: Atenolol 50 mg once daily + HCTZ 25 mg once daily for 10 weeks
Number of subjects: 118
Study: 6116461

Group type: EXPERIMENTAL
Intervention: Alfentanil (0.5 mg/ml)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Fentanyl (0.05 mg/ml)
Number of subjects: 90
Study: 31813332

Group type: EXPERIMENTAL
Intervention: Mental Practice (MP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical Practice (PP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mental Practice (MP) alone
Number of subjects: 0
Study: 31097414

Group type: EXPERIMENTAL
Intervention: Stepped-care intervention (eight sessions of individual problem-solving therapy, with an extra two to four sessions if needed) plus enhanced usual care
Number of subjects: 1178

Group type: COMPARATOR
Intervention: Enhanced usual care only
Number of subjects: 1178
Study: 28256070

Group type: EXPERIMENTAL
Intervention: ProNutrients® Probiotic powder sachet containing BB-12 and LGG
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsupplemented control group
Number of subjects: 0
Study: 25874938

Group type: EXPERIMENTAL
Intervention: Auricular acupressure (AA) on specific acupoints
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sham auricular acupressure (SAA) on non-specific acupoints
Number of subjects: 63
Study: 23691203

Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control
Number of subjects: 240
Study: 21048041

Group type: EXPERIMENTAL
Intervention: CAPOX-B (capecitabine, oxaliplatin, and bevacizumab)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Beneficial genetic profile (TYMS enhancer region and VEGF +405G>C polymorphisms)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Unfavorable genetic profile (not specified)
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: CAPOX-B
Number of subjects: 279
Study: 19265317

Group type: EXPERIMENTAL
Intervention: Exercise program for 16 weeks
Number of subjects: 70
Study: 17101741

Group type: EXPERIMENTAL
Intervention: NXY-059 (15 mg/mL) during 12 hours
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study: 12800796

Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination chemotherapy and radiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intraperitoneal treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immunotherapy
Number of subjects: 0
Study: 11155057

Group type: EXPERIMENTAL
Intervention: Remifentanil hydrochloride, bolus doses of 1 microgram/kg followed by continuous infusions of 0.1‐0.5 microgram/kg/min, titrated to effect.
Number of subjects: 2
Study: 9124202

Group type: EXPERIMENTAL
Intervention: G‐CSF (arm A)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: G‐CSF followed by GM‐CSF (arm B)
Number of subjects: 10
Study: 8268729

Group type: EXPERIMENTAL
Intervention: Org 2766
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clinical function testing and myometry
Number of subjects: 24
Study: 3703481

Group type: EXPERIMENTAL
Intervention: Interferon-beta (IFN-beta) eye drops
Number of subjects: 20

Group type: COMPARATOR
Intervention: Iododesoxyuridine eye drops
Number of subjects: 20
Study: 31567574

Group type: EXPERIMENTAL
Intervention: Thromboelastometry-guided transfusion algorithm
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard coagulation test algorithm
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 81
Study: 29095347

Group type: EXPERIMENTAL
Intervention: Spoon-fed amino acid-based formula (AAF) with a yogurt-type texture (group 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference oral liquid formula (Neocate) (group 2)
Number of subjects: 0
Study: 26373657

Group type: EXPERIMENTAL
Intervention: Longitudinal care (telephone-based counseling and nicotine replacement therapy for 12 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (standard 8-week treatment)
Number of subjects: 0
Study: 24639438

Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion intervention based on WHO/UNICEF Baby‐Friendly Hospital Initiative
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard practices (control group)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion intervention
Number of subjects: 31
Study: 22464164

Group type: EXPERIMENTAL
Intervention: HES 130/0.4 preload (500 mL)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline solution preload (1000 mL)
Number of subjects: 60
Study: 20040880

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular exercise training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High relative intensity exercise training
Number of subjects: 0
Study: 17618447

Group type: EXPERIMENTAL
Intervention: Levocabastine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 40

Group type: COMPARATOR
Intervention: No pre-treatment
Number of subjects: 40
Study: 16117771

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) instilled locally before implant placement
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no PRP)
Number of subjects: 10
Study: 12324668

Group type: EXPERIMENTAL
Intervention: Daily rhDNase (2.5 mg once daily)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Alternate day rhDNase (2.5 mg every other day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Hypertonic saline (5 ml 7% HS twice daily)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Daily rhDNase
Number of subjects: 48
Study: 12080402

Group type: EXPERIMENTAL
Intervention: Walnut diet (12.5% of energy from walnuts, 44-58 g/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Walnut diet
Number of subjects: 40
Study: 9733272

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CP) at a dose of 50 mg/kg daily infused intravenously over 1 hour for 4 days (in aplastic anemia patients)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CP) at a dose of 60 mg/kg by i.v. infusion over 1 hour daily for 2 days followed by total body irradiation (in leukemia patients)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Patients who developed hemorrhagic cystitis (HC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Rest of the patients (without HC)
Number of subjects: 16
Study: 8296403

Group type: EXPERIMENTAL
Intervention: Intermittent suction and pressure (Vacusac treatment)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo applications
Number of subjects: 22
Study: 3180634

Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 29453785

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-soaked gauze
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chlorhexidine mouth rinse
Number of subjects: 60
Study: 28202500

Group type: EXPERIMENTAL
Intervention: Walking intervention comprising Macmillan's 'Move More' information, a short motivational interview recommending to walk for at least 30 minutes on alternate days and attend a volunteer-led group walk weekly.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 42
Study: 26144276

Group type: EXPERIMENTAL
Intervention: Log book (LB) support for secondary prevention (SP) after acute MI (LB+ group)
Number of subjects: 183
Study: 24122045

Group type: EXPERIMENTAL
Intervention: Bipolar hemiarthroplasty
Number of subjects: 120

Group type: COMPARATOR
Intervention: Unipolar hemiarthroplasty
Number of subjects: 120
Study: 21508653

Group type: EXPERIMENTAL
Intervention: Low-flow sevoflurane supplemented with remifentanil (group SR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low-flow sevoflurane (group S)
Number of subjects: 50
Study: 18675597

Group type: EXPERIMENTAL
Intervention: Endometrial aspiration before saline infusion sonography (SIS)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Saline infusion sonography (SIS) before endometrial aspiration
Number of subjects: 113
Study: 16427019

Group type: EXPERIMENTAL
Intervention: Street-level advertisements (SLAs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Raised-level advertisements (RLAs)
Number of subjects: 0
Study: 12867217

Group type: EXPERIMENTAL
Intervention: Aprepitant 375 mg PO, dexamethasone 20 mg PO, ondansetron 32 mg IV on day 1, followed by aprepitant 250 mg PO and dexamethasone 8 mg PO on days 2 through 5
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg PO with granisetron 2 mg PO on day 1, followed by aprepitant 80 mg PO on days 2 and 3
Number of subjects: 37

Group type: COMPARATOR
Intervention: Dexamethasone 20 mg PO and ondansetron 32 mg IV on day 1, followed by dexamethasone 8 mg PO on days 2 through 5
Number of subjects: 37

Group type: COMPARATOR
Intervention: Granisetron 2 mg PO on day 1 only
Number of subjects: 37
Study: 11152085

Group type: EXPERIMENTAL
Intervention: Payment in advance
Number of subjects: 583

Group type: COMPARATOR
Intervention: Payment on completion
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Overall response rate
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Effect of timing of incentives
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness
Number of subjects: 583
Study: 9194649

Group type: EXPERIMENTAL
Intervention: 2, 4 or 8 mg of micronized MENT (single i.m. injections)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 1, 2 or 4 mg of MENT (six consecutive daily i.m. injections)
Number of subjects: 42
Study: 1587077

Group type: EXPERIMENTAL
Intervention: Continuous medication
Number of subjects: 121

Group type: COMPARATOR
Intervention: Targeted intermittent medication
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Upward dose adjustment
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Initial beneficial effect (greater than or equal to 6 months of weight loss greater than or equal to 10% from baseline)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Weight loss at week 160
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Weight loss at week 190
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Dropout successes
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Dropouts with initial benefit
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Minimal benefit in dropouts
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Dropouts in study less than 1 year
Number of subjects: 121
Study: 30732920

Group type: EXPERIMENTAL
Intervention: Guided surgery group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 28285608

Group type: EXPERIMENTAL
Intervention: High glycaemic index (GI) breakfast
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low glycaemic index (GI) breakfast
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both high and low GI breakfasts
Number of subjects: 40
Study: 25229641

Group type: EXPERIMENTAL
Intervention: Caries resin infiltration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride (SDF) application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 23886736

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention for anxiety
Number of subjects: 1004
Study: 21359903

Group type: EXPERIMENTAL
Intervention: INtraoperative Video‐Enhanced Surgical Training (INVEST)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Master‐Apprentice Model (MAM)
Number of subjects: 10
Study: 19638205

Group type: EXPERIMENTAL
Intervention: Pain frequency and severity (measured using 24 item Geriatric Pain Measure)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Difficulties with basic ADLs
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Risk for social isolation (measured using 6 item Lubben Social Network scale)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Basic education only
Number of subjects: 406
Study: 16393295

Group type: EXPERIMENTAL
Intervention: GERD patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) >25%
Number of subjects: 0
Study: 15242436

Group type: EXPERIMENTAL
Intervention: 65% nitrous oxide
Number of subjects: 344

Group type: COMPARATOR
Intervention: 65% nitrogen in air (control)
Number of subjects: 344